Ensayos Clínicos
Centros: Hospital Universitari Vall d’Hebron (Barcelona) – Dr. David Beneitez, Hospital Universitario La Paz (Madrid) – Dra. Marta Morado.
A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy (STEADFAST).
Centros: Hospital Universitario Gregorio Marañón (Madrid) – Dra. Gloria Pérez Rus, Hospital Universitari Vall d’Hebron (Barcelona) – Dr. David Beneitez.
PRAISE: An adaptive, randomized, placebo controlled, double-blind, multicenter study of oral FT-4202, a Pyruvate Kinase activator in patients with sickle cell disease
Centros: Hospital Universitario La Paz (Madrid) – Dra. Marta Morado, Hospital Universitari Vall d’Hebron (Barcelona) – Dr. David Beneitez.
AG946-C-001 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Subjects with Sickle Cell Disease.
Centro: Hospital Clínico Universitario Virgen de la Arrixaca (Murcia) – Dr. Eduardo José Salido Fiérrez.
BO42452/ A Phase Ib Randomized, Placebo-Controlled Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Crovalimab For The Management Of Acute Uncomplicated Vaso-Cclusive Episodes (VOE) In Patients With Sickle Cell Disease (SCD)
Centro: Hospital Universitari Vall d´Hebron (Barcelona) – Dr. David Beneitez.
BO42451/ A Randomized Double-Blind Phase 2a Study Evaluating The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Crovalimab As Adjunct Treatment In Prevention Of Acute Vaso-Occlusive Episodes (VOE) In Sickle Cell Disease (SCD)
Centro: Hospital Universitari Vall d’Hebron (Barcelona) – Dr. David Beneitez.
